(Q33757677)

29 July 2017

1 reference

title

Intraperitoneal chemotherapy (English)

1 reference

29 July 2017

1 reference

Markman M

1

1 reference

29 July 2017

publication date

1 August 1999

1 reference

29 July 2017

number of pages

8

1 reference

Critical Reviews in Oncology Hematology

inferred from page(s)

published in

1 reference

29 July 2017

volume

31

1 reference

29 July 2017

issue

3

1 reference

29 July 2017

page(s)

239-246

1 reference

Use of nitrogen mustard in treatment of serous effusions of neoplastic origin

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900017-7

7 January 2021

Intraperitoneal therapy for treatment of malignant disease principally confined to the peritoneal cavity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900017-7

7 January 2021

Intraperitoneal cisplatin with systemic thiosulfate protection

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900017-7

7 January 2021

Clinical pharmacology of intraperitoneal cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900017-7

7 January 2021

Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900017-7

7 January 2021

Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900017-7

7 January 2021

Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900017-7

7 January 2021

Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: Lessons learned from a gynecologic oncology group phase II trial of ip cisplatin and recombinant α-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900017-7

7 January 2021

Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900017-7

7 January 2021

Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900017-7

7 January 2021

Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900017-7

7 January 2021

Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900017-7

7 January 2021

Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900017-7

7 January 2021

Evaluation of survival after second-line intraperitoneal cisplatin-based chemotherapy for advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900017-7

7 January 2021

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900017-7

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900017-7

7 January 2021

High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900017-7

7 January 2021

Recurrence after negative second-look laparotomy for ovarian cancer: analysis of risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900017-7

7 January 2021

A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with Stage II-IV epithelial ovarian cancer following negative surgical assessment

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900017-7

7 January 2021

Pentetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900017-7

7 January 2021

Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900017-7

7 January 2021

Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900017-7

7 January 2021

Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900017-7

7 January 2021

Early peritoneal mesothelioma: a treatable malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900017-7

7 January 2021

Long-term survival in peritoneal mesothelioma. The role of radiotherapy and combined modality treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900017-7

7 January 2021

Is There a Role for Intraperitoneal Therapy in the Management of Gastrointestinal Malignancies?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900017-7

7 January 2021

Peritoneal carcinomatosis from appendiceal cancer: results in 69 patients treated by cytoreductive surgery and intraperitoneal chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900017-7

7 January 2021

A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900017-7

7 January 2021

Prophylaxis with carbon-adsorbed mitomycin against peritoneal recurrence of gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900017-7

7 January 2021

Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900017-7

7 January 2021

10.1016/S1040-8428(99)00017-7

Identifiers

DOI

1 reference

29 July 2017

1 reference